JMP Securities Maintains CRISPR Therapeutics(CRSP.US) With Buy Rating, Maintains Target Price $86
CRISPR Therapeutics: Promising Developments and Positive Outlook Amid Advancements in Gene-Editing
1 Big New Green Flag for CRISPR Therapeutics' Stock
Express News | JMP Securities Reiterates Market Outperform on CRISPR Therapeutics, Maintains $86 Price Target
Clear Street Initiates CRISPR Therapeutics(CRSP.US) With Hold Rating, Announces Target Price $45
Trending Industry Today: Beam Therapeutics Leads Losses In Gene Editing Stocks
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
